Chronic Kidney Disease (CKD) — CKD progression and nephron loss consequences - Pathophysiology

SECTION 1

Historical Context & Motivation

The concept of chronic kidney disease has evolved dramatically over the past century, moving from a purely clinical observation of uremia to a sophisticated understanding of nephron-level pathophysiology. Early clinicians recognized that patients with damaged kidneys progressively lost function, but the mechanisms underlying this relentless decline remained obscure for decades. The pivotal insight — that the kidney's compensatory response to nephron loss paradoxically accelerates further damage — transformed our understanding of renal disease and reshaped therapeutic strategies. Today, CKD affects approximately 15% of the adult population in the United States, and understanding the pathophysiological cascade of nephron loss is essential for any healthcare provider managing these patients.

1836 • Bright's Disease Described

Richard Bright correlated proteinuria with renal structural changes at autopsy, establishing the first clinical-pathological framework for chronic renal disease — then known as Bright's disease.

1960s • Bricker's Intact Nephron Hypothesis

Neal Bricker proposed that surviving nephrons in a diseased kidney undergo functional hypertrophy, maintaining overall homeostasis until a critical mass of nephrons is lost. This intact nephron hypothesis became foundational to understanding CKD progression.

1982 • Brenner's Hyperfiltration Theory

Barry Brenner and colleagues demonstrated in the remnant kidney model that compensatory glomerular hyperfiltration contributes to progressive glomerulosclerosis, establishing the mechanistic link between nephron loss and ongoing renal injury.

2002 • KDOQI Classification

The National Kidney Foundation's Kidney Disease Outcomes Quality Initiative (KDOQI) published standardized CKD staging based on glomerular filtration rate (GFR), providing a universal framework for classifying disease severity.

2012 • KDIGO CGA Classification

Kidney Disease: Improving Global Outcomes (KDIGO) refined CKD staging by incorporating albuminuria categories alongside GFR, enabling more precise risk stratification and prognosis.

The central question that emerges from this historical trajectory is both clinically urgent and mechanistically fascinating: why does the loss of a subset of nephrons invariably lead to the loss of more nephrons? Understanding this self-perpetuating cycle — from initial injury through maladaptive compensation to systemic consequences — is the core objective of this lesson.

SECTION 2

Core Principles of CKD Progression

CKD progression rests on a set of interconnected pathophysiological principles that explain how an initial insult to the kidney — whether from diabetes, hypertension, glomerulonephritis, or other causes — sets in motion a cascade of events culminating in end-stage renal disease (ESRD). These principles bridge the molecular, cellular, and organ-system levels and are essential for understanding both disease monitoring and therapeutic intervention.

Nephron Loss & Functional Adaptation

When nephrons are destroyed, remaining nephrons compensate by increasing their individual single-nephron GFR (SNGFR) through glomerular hypertrophy and hyperfiltration, temporarily maintaining total kidney GFR.

Maladaptive Hyperfiltration

Elevated glomerular capillary pressure in surviving nephrons causes endothelial injury, podocyte damage, mesangial expansion, and progressive glomerulosclerosis, destroying the very nephrons attempting to compensate.

Tubulointerstitial Fibrosis

Proteinuria from damaged glomeruli triggers tubular epithelial cells to release pro-inflammatory cytokines and profibrotic mediators, driving tubulointerstitial fibrosis — the strongest histological predictor of CKD progression.

RAAS Activation

Nephron loss activates the renin-angiotensin-aldosterone system (RAAS). Angiotensin II constricts the efferent arteriole, raising intraglomerular pressure and promoting proteinuria, fibrosis, and oxidative stress in a self-amplifying feedback loop.

Systemic Consequences

As total GFR falls below critical thresholds, the kidney can no longer maintain fluid balance, electrolyte homeostasis, acid-base regulation, or endocrine functions, leading to uremia, metabolic acidosis, hyperkalemia, anemia, and renal osteodystrophy.

✦

KEY TAKEAWAY

Think of nephron loss like removing lanes from a highway during rush hour. The remaining lanes must carry all the traffic, so each lane becomes congested and stressed. Over time, this excessive stress causes potholes and structural damage in those remaining lanes, forcing even more lanes to close — creating a vicious cycle that eventually shuts down the entire highway. In the kidney, compensatory hyperfiltration is the renal equivalent of this traffic overload: it temporarily maintains throughput but inevitably destroys the infrastructure it depends on.

SECTION 3

The Vicious Cycle of Nephron Loss

The following diagram illustrates the self-perpetuating cycle that drives CKD progression. An initial insult destroys a population of nephrons, which triggers compensatory changes in the survivors. These compensatory changes, while initially beneficial for maintaining GFR, ultimately cause further nephron destruction. Understanding this cycle is critical because it identifies multiple therapeutic targets — most notably the RAAS — where intervention can slow or interrupt the feedback loop.

The diagram traces how initial nephron loss leads to compensatory single-nephron hyperfiltration, which raises intraglomerular pressure. This elevated pressure injures the filtration barrier (endothelium, basement membrane, podocytes), resulting in proteinuria and inflammation. The ensuing glomerulosclerosis and tubulointerstitial fibrosis destroy additional nephrons (dashed red feedback arrow), perpetuating the cycle. The purple inset highlights RAAS activation as a key amplifier — and therapeutic target — in this cascade.

Note the dashed feedback arrow on the right side of the diagram: this represents the critical transition from adaptive compensation to maladaptive destruction. As long as this cycle continues unchecked, the kidney marches inexorably toward ESRD. The therapeutic significance of RAAS blockade with ACE inhibitors or angiotensin receptor blockers lies precisely in its ability to reduce intraglomerular pressure, thereby slowing the transition from the second to the third box in this sequence.

SECTION 4

Hemodynamic & Molecular Mechanisms

Glomerular Hemodynamics and GFR Determinants

The glomerular filtration rate at the level of a single nephron is governed by Starling forces across the glomerular capillary membrane. The key equation describing this relationship expresses SNGFR as the product of the ultrafiltration coefficient and the net filtration pressure. Understanding each variable in this equation reveals precisely how nephron loss translates to hemodynamic stress.

SINGLE-NEPHRON GFR

SNGFR = K_f × (P_GC − P_BS − π_GC)

Where K_f = ultrafiltration coefficient (hydraulic permeability × surface area), P_GC = glomerular capillary hydrostatic pressure, P_BS = Bowman space hydrostatic pressure, π_GC = glomerular capillary oncotic pressure. In nephron loss, the surviving nephrons increase P_GC through afferent arteriole dilation and efferent arteriole constriction to raise SNGFR.

TOTAL GFR FROM NEPHRON COUNT

GFR_total = N × SNGFR

Where N = number of functioning nephrons and SNGFR = single-nephron glomerular filtration rate. As N decreases, SNGFR must increase proportionally to maintain total GFR — this is the essence of the compensatory hyperfiltration response.

Cockcroft-Gault & CKD-EPI Equations

COCKCROFT-GAULT CREATININE CLEARANCE

CrCl = [(140 − age) × weight (kg)] / [72 × S_Cr (mg/dL)] × 0.85 (if female)

This equation estimates creatinine clearance as a surrogate for GFR. As nephrons are lost and GFR falls, serum creatinine (S_Cr) rises because fewer nephrons are available to filter and secrete creatinine. However, because surviving nephrons hypersecrete creatinine, S_Cr may remain deceptively normal until approximately 50% of nephrons are lost — the so-called creatinine-blind range.

Molecular Mediators of Fibrosis

At the molecular level, several mediators drive the transition from compensatory adaptation to irreversible fibrosis. Transforming growth factor-β (TGF-β) is the master profibrotic cytokine, stimulating mesangial cells, tubular epithelial cells, and fibroblasts to produce excessive extracellular matrix. Angiotensin II directly upregulates TGF-β expression, providing the mechanistic link between RAAS activation and fibrosis. Additionally, reactive oxygen species (ROS) generated by the hyperfiltrating nephrons cause lipid peroxidation and protein oxidation, further damaging tubular cells. Filtered proteins — particularly albumin — are reabsorbed by proximal tubular cells via megalin and cubilin receptors, activating NF-κB signaling pathways that drive chemokine secretion (MCP-1, RANTES) and recruit inflammatory cells into the interstitium. This inflammatory infiltrate produces additional TGF-β and other profibrotic mediators, creating a molecular amplification loop that mirrors the hemodynamic vicious cycle.

SECTION 5

CKD Staging and Systemic Consequences of Nephron Loss

The KDIGO classification system stages CKD according to estimated GFR and albuminuria. Each stage corresponds to a different degree of nephron loss and a distinct profile of systemic consequences as the kidney progressively fails to maintain its excretory, regulatory, and endocrine functions.

Stage	eGFR (mL/min/1.73 m²)	Description	Key Consequences
G1	≥ 90	Normal or high GFR with evidence of kidney damage (proteinuria, structural abnormality)	Hyperfiltration begins; often asymptomatic; early albuminuria detectable
G2	60–89	Mild decrease in GFR	Mild ↑ PTH begins; concentration defect may emerge
G3a	45–59	Mild-to-moderate decrease	↓ Calcitriol synthesis; calcium and phosphorus imbalances begin; early anemia
G3b	30–44	Moderate-to-severe decrease	↑ Phosphorus retention; significant ↓ erythropoietin → anemia; metabolic acidosis begins
G4	15–29	Severe decrease	Hyperkalemia; volume overload; ↑ uremic toxins; cardiovascular risk markedly elevated
G5	< 15	Kidney failure (ESRD)	Uremia; pericarditis; encephalopathy; dialysis or transplant required

KDIGO GFR categories with corresponding nephron loss consequences

This graph depicts the typical trajectory of eGFR decline over time, with color-coded CKD stages (G1–G5) and labels indicating the predominant systemic complications emerging at each level. Note the initial plateau during the hyperfiltration phase (G1/G2), where SNGFR compensation masks total nephron loss, followed by accelerating decline as compensatory capacity is exhausted.

Major Systemic Consequences in Detail

CKD-Mineral and Bone Disorder (CKD-MBD): Reduced nephron mass diminishes 1α-hydroxylase activity, decreasing calcitriol production. Hyperphosphatemia (due to reduced phosphate excretion) further suppresses calcitriol and elevates fibroblast growth factor 23 (FGF-23). The resulting secondary hyperparathyroidism drives bone resorption (renal osteodystrophy) and vascular calcification.
Anemia of CKD: Peritubular fibroblasts in the renal cortex produce erythropoietin (EPO). As nephrons are lost and the interstitium becomes fibrotic, EPO production declines, resulting in a normocytic, normochromic anemia that typically becomes clinically significant at GFR < 30–45 mL/min.
Metabolic Acidosis: The kidney normally regenerates bicarbonate and excretes ammonium (NH₄⁺). With nephron loss, total ammonium excretion falls even though per-nephron ammoniagenesis increases. Below GFR ≈ 25, acid accumulates, causing a non-anion-gap metabolic acidosis that may progress to an elevated anion-gap pattern as uremic organic acids accumulate.
Hyperkalemia: Potassium excretion depends on distal tubular flow and aldosterone-mediated secretion. In advanced CKD, reduced nephron mass limits K⁺ secretory capacity, and concurrent use of RAAS inhibitors or potassium-sparing diuretics further elevates the risk of life-threatening hyperkalemia.
Cardiovascular Disease: CKD is an independent risk factor for cardiovascular morbidity and mortality. Volume overload, hypertension, dyslipidemia, uremic toxins (indoxyl sulfate, p-cresyl sulfate), chronic inflammation, and vascular calcification synergistically promote left ventricular hypertrophy, atherosclerosis, and heart failure.

SECTION 6

Worked Example: Tracking CKD Progression

Consider a 62-year-old male patient (weight 80 kg) with type 2 diabetes mellitus who has been followed for progressive CKD. His serum creatinine (S_Cr) has risen from 1.2 mg/dL two years ago to 2.4 mg/dL today. We will estimate his creatinine clearance at both time points and calculate the rate of GFR decline to assess CKD stage and predict trajectory.

Estimating CKD Progression Using Cockcroft-Gault

1
Step 1 — Identify Given Values

Age = 62 years, Weight = 80 kg, Sex = male (no correction factor). At baseline: S_Cr = 1.2 mg/dL. At present (2 years later): S_Cr = 2.4 mg/dL.
2
Step 2 — Calculate Baseline Creatinine Clearance

Using the Cockcroft-Gault equation: CrCl = [(140 − 62) × 80] / [72 × 1.2] = [78 × 80] / [86.4] = 6240 / 86.4 ≈ 72.2 mL/min. At baseline, this places the patient in CKD Stage G2 (eGFR 60–89), consistent with mild kidney damage in a diabetic patient with albuminuria.

Baseline CrCl ≈ 72.2 mL/min (Stage G2)
3
Step 3 — Calculate Present Creatinine Clearance

CrCl = [(140 − 64) × 80] / [72 × 2.4] = [76 × 80] / [172.8] = 6080 / 172.8 ≈ 35.2 mL/min. Note: we use age 64 because 2 years have elapsed. The patient has now progressed to CKD Stage G3b (eGFR 30–44).

Present CrCl ≈ 35.2 mL/min (Stage G3b)
4
Step 4 — Calculate Rate of GFR Decline

Rate of decline = (72.2 − 35.2) / 2 years = 37.0 / 2 = 18.5 mL/min per year. The normal age-related decline in GFR is approximately 1 mL/min/year after age 40. This patient's rate of 18.5 mL/min/year is markedly accelerated, indicating aggressive CKD progression. A decline exceeding 5 mL/min/year is considered rapid and warrants urgent evaluation and intensification of nephroprotective therapy.

Rate of decline = 18.5 mL/min/year — rapid progression
5
Step 5 — Clinical Interpretation & Predicted Consequences

At Stage G3b, we expect this patient to exhibit early anemia (decreased EPO production), metabolic acidosis (reduced ammonium excretion), and CKD-MBD (elevated PTH, rising phosphate, declining calcitriol). The rapid progression suggests inadequate RAAS blockade, uncontrolled glycemia, or both. If this rate continues, the patient will reach ESRD (GFR < 15) in approximately (35.2 − 15) / 18.5 ≈ 1.1 years — emphasizing the urgency of intervention.

Predicted time to ESRD ≈ 1.1 years without intervention

SECTION 7

Therapeutic Strategies: Targets and Limitations

Understanding the mechanisms of nephron loss provides a rational basis for therapeutic intervention at multiple points in the progression cascade. The following table summarizes the major nephroprotective strategies, their mechanisms, and their limitations.

Intervention	Mechanism of Action	Limitations / Risks
ACE Inhibitors / ARBs	Dilate efferent arteriole → ↓ P_GC → ↓ hyperfiltration injury and proteinuria; reduce TGF-β expression	Acute ↓ GFR upon initiation (up to 30% is acceptable); hyperkalemia risk; contraindicated in bilateral renal artery stenosis
SGLT2 Inhibitors	Restore tubuloglomerular feedback by increasing NaCl delivery to macula densa → afferent arteriolar constriction → ↓ P_GC	Risk of euglycemic DKA; genital mycotic infections; initial transient ↓ eGFR; limited efficacy at very low GFR
Blood Pressure Control	Target < 130/80 mmHg reduces transmitted systemic pressure to glomeruli; ↓ mechanical stress on capillary walls	Overly aggressive BP lowering may reduce renal perfusion; individual target varies with age, comorbidities
Glycemic Control (DM)	Reduces AGE formation, PKC activation, and polyol pathway flux; ↓ mesangial expansion and basement membrane thickening	Tight control increases hypoglycemia risk; insulin dosing must be adjusted as GFR falls (↓ insulin clearance)
Dietary Protein Restriction	Reduces amino acid-mediated afferent arteriolar dilation → ↓ glomerular plasma flow and P_GC	Risk of malnutrition; adherence challenges; modest benefit in trials; not recommended below 0.6 g/kg/day

Major nephroprotective strategies and their limitations

✦

KEY TAKEAWAY

The therapeutic paradigm in CKD has shifted from simply waiting for ESRD and dialysis to proactive interruption of the hyperfiltration-fibrosis cycle. ACE inhibitors, ARBs, and SGLT2 inhibitors each target the glomerular hemodynamic derangement from different angles — analogous to applying brakes at multiple points on a runaway conveyor belt. The initial dip in GFR seen with RAAS inhibitors or SGLT2 inhibitors represents the reduction in pathological hyperfiltration and is therapeutically desirable, not harmful.

SECTION 8

Connections to Advanced Renal Pathophysiology

The principles of CKD progression and nephron loss form the foundation for understanding several advanced topics in renal pathophysiology. The table below maps each core concept from this lesson to its extension in more advanced clinical and research contexts.

Core Concept (This Lesson)	Advanced Extension
Compensatory hyperfiltration	Obesity-related glomerulopathy: hyperfiltration in obese patients with full nephron endowment demonstrates that excessive SNGFR causes disease even without initial nephron loss
Creatinine as a GFR marker	Cystatin C-based GFR estimation overcomes the limitations of creatinine (muscle mass dependence, tubular secretion), providing more accurate staging in sarcopenic or obese patients
TGF-β-driven fibrosis	Epithelial-to-mesenchymal transition (EMT) — tubular cells transdifferentiate into myofibroblasts under TGF-β stimulation, contributing to interstitial scar formation and representing a potential drug target
CKD-MBD	FGF-23/Klotho axis: FGF-23 rises before PTH or phosphorus in early CKD and is an independent predictor of cardiovascular mortality; Klotho deficiency accelerates vascular calcification and aging-like phenotypes
RAAS blockade	Non-steroidal mineralocorticoid receptor antagonists (finerenone) and endothelin receptor antagonists (atrasentan) represent emerging therapies that target inflammation and fibrosis beyond hemodynamic effects

From foundational CKD concepts to advanced renal pathophysiology

A particularly active area of research involves nephron endowment — the number of nephrons an individual is born with, which can vary from approximately 200,000 to over 2,000,000 per kidney. Low birth weight, prematurity, and maternal malnutrition are associated with reduced nephron endowment, predisposing individuals to hypertension and CKD later in life. This concept, rooted in Barker's developmental origins of disease hypothesis, reframes CKD as a condition that may begin in utero, decades before any clinical manifestation.

SECTION 9

Practice Problems

Question 1: CONCEPTUAL

Explain why serum creatinine may remain within the normal reference range (0.7–1.3 mg/dL) even after a patient has lost approximately 50% of their nephrons. What implications does this have for early CKD detection?

Show answer

Serum creatinine is determined by the balance between creatinine production (from muscle metabolism, relatively constant in a given individual) and creatinine excretion (via glomerular filtration and tubular secretion). When nephrons are lost, the surviving nephrons increase their individual filtration rate (hyperfiltration) and tubular creatinine secretion, collectively maintaining total creatinine excretion near normal levels. Consequently, serum creatinine does not rise appreciably until roughly half of nephron function is lost — this phenomenon defines the creatinine-blind range. The clinical implication is that relying solely on serum creatinine will miss early CKD; screening should incorporate albuminuria measurement and estimated GFR equations that account for age, sex, and body composition.

Question 2: BASIC CALCULATION

A 55-year-old woman weighing 65 kg has a serum creatinine of 1.8 mg/dL. Using the Cockcroft-Gault equation, estimate her creatinine clearance and assign the appropriate CKD stage.

Show answer

Applying the Cockcroft-Gault equation: CrCl = [(140 − 55) × 65] / [72 × 1.8] × 0.85 = [85 × 65] / [129.6] × 0.85 = 5525 / 129.6 × 0.85 = 42.6 × 0.85 ≈ 36.2 mL/min. The 0.85 correction factor is applied because the patient is female (lower creatinine generation due to lower average muscle mass). A CrCl of 36.2 mL/min corresponds to CKD Stage G3b (eGFR 30–44 mL/min/1.73 m²). At this stage, we would expect emerging anemia from decreased EPO production, early metabolic acidosis, and CKD-MBD with rising PTH levels.

Question 3: INTERMEDIATE

A patient with CKD Stage G3a is started on an ACE inhibitor. Two weeks later, lab work reveals that eGFR has decreased from 52 to 42 mL/min/1.73 m² and serum potassium has risen from 4.5 to 5.4 mEq/L. Should the ACE inhibitor be continued, dose-adjusted, or discontinued? Justify your answer using the hemodynamic principles discussed in this lesson.

Show answer

The eGFR decrease of approximately 19% is within the acceptable range of up to 30% that is expected upon RAAS inhibitor initiation. This drop reflects the desired reduction in efferent arteriolar tone, which lowers glomerular capillary pressure (P_GC) and therefore reduces SNGFR — the therapeutic goal. However, the potassium of 5.4 mEq/L warrants monitoring. At this level, the ACE inhibitor should be continued with close follow-up. Interventions for hyperkalemia (dietary potassium restriction, loop diuretics, or potassium binders such as patiromer) should be considered rather than discontinuing the nephroprotective agent. The ACE inhibitor should only be discontinued if potassium exceeds 5.5 mEq/L persistently despite management, or if eGFR declines more than 30% from baseline.

Question 4: APPLIED

A 58-year-old patient with CKD Stage G4 (eGFR = 22 mL/min) presents with fatigue, hemoglobin of 8.9 g/dL, calcium of 8.2 mg/dL (low-normal), phosphorus of 6.1 mg/dL (elevated), and PTH of 280 pg/mL (markedly elevated). Explain the pathophysiological connections between nephron loss and each of these laboratory findings, referencing specific renal functions that are impaired.

Show answer

Each lab abnormality traces directly to specific consequences of nephron loss. The low hemoglobin (8.9 g/dL) reflects decreased erythropoietin production by fibrotic peritubular fibroblasts, resulting in anemia of CKD. The elevated phosphorus (6.1 mg/dL) results from reduced phosphate excretion as functioning nephron mass declines — fewer nephrons means less proximal tubular phosphate handling despite per-nephron compensation. The low-normal calcium reflects decreased 1,25-dihydroxyvitamin D (calcitriol) synthesis because the remaining proximal tubular cells have insufficient 1α-hydroxylase capacity; additionally, hyperphosphatemia directly inhibits 1α-hydroxylase. The markedly elevated PTH (280 pg/mL) represents secondary hyperparathyroidism — a compensatory response to hypocalcemia, hyperphosphatemia, and calcitriol deficiency. This constellation defines CKD-Mineral and Bone Disorder (CKD-MBD), which predisposes to renal osteodystrophy and vascular calcification.

Question 5: CRITICAL THINKING

Living kidney donors voluntarily undergo a 50% nephron reduction. Yet most donors do not develop CKD or significant proteinuria. How does this observation challenge or refine Brenner's hyperfiltration theory? Consider the roles of nephron endowment, comorbidity burden, and the magnitude of hyperfiltration in your analysis.

Show answer

This observation does not refute Brenner's theory but rather refines it by demonstrating that hyperfiltration alone is not sufficient to cause progressive CKD in a kidney that is otherwise healthy. In Brenner's original remnant kidney model, the 5/6 nephrectomy removed approximately 83% of nephrons — a far more extreme reduction than the donor's 50%. The degree of compensatory hyperfiltration per remaining nephron in a donor is therefore substantially less than in the experimental model, and the increase in P_GC may remain below the threshold that triggers endothelial and podocyte injury. Furthermore, healthy donors are screened to exclude diabetes, hypertension, and proteinuria — precisely the comorbidities that create a 'second hit' amplifying the damage from hyperfiltration. The concept of nephron endowment is also relevant: a donor born with 2 million nephrons who donates one kidney retains 1 million — a robust reserve. A donor born with only 500,000 nephrons per kidney would be left with a much smaller margin, potentially explaining the small subset of donors who do develop late CKD. Thus, CKD progression is best understood as a threshold phenomenon requiring sufficient hyperfiltration magnitude, duration, and coexisting injurious factors.

SUMMARY

Summary

Chronic kidney disease progresses through a self-perpetuating cycle in which initial nephron loss from any cause (diabetes, hypertension, glomerulonephritis) triggers compensatory hyperfiltration in surviving nephrons. This increase in single-nephron GFR is driven by elevated intraglomerular capillary pressure (P_GC), amplified by RAAS activation and angiotensin II-mediated efferent arteriolar constriction. While initially maintaining total GFR, this hemodynamic stress causes endothelial injury, podocyte loss, proteinuria, and ultimately glomerulosclerosis and tubulointerstitial fibrosis — destroying additional nephrons and perpetuating the vicious cycle.

As total GFR declines through KDIGO stages G1–G5, systemic consequences emerge in a predictable sequence: CKD-Mineral and Bone Disorder (decreased calcitriol, hyperphosphatemia, secondary hyperparathyroidism), anemia (decreased EPO), metabolic acidosis (decreased ammonium excretion), hyperkalemia, and ultimately uremia. Therapeutic strategies — ACE inhibitors/ARBs, SGLT2 inhibitors, blood pressure control, glycemic management, and dietary modification — all target the hemodynamic and molecular amplifiers of this cycle, aiming to slow progression and delay the need for renal replacement therapy.